CN104225681B - A kind of tissue engineered bone and preparation method thereof - Google Patents
A kind of tissue engineered bone and preparation method thereof Download PDFInfo
- Publication number
- CN104225681B CN104225681B CN201410480554.6A CN201410480554A CN104225681B CN 104225681 B CN104225681 B CN 104225681B CN 201410480554 A CN201410480554 A CN 201410480554A CN 104225681 B CN104225681 B CN 104225681B
- Authority
- CN
- China
- Prior art keywords
- mesenchymal stem
- stem cells
- sheet
- cells mscs
- culture dish
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001519 tissue Anatomy 0.000 title claims abstract description 50
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims abstract description 65
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 51
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 238000003475 lamination Methods 0.000 claims abstract description 20
- 230000001413 cellular effect Effects 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 13
- 210000003556 vascular endothelial cell Anatomy 0.000 claims abstract description 12
- 239000001963 growth medium Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000006185 dispersion Substances 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 7
- 230000001464 adherent effect Effects 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
- 229960003957 dexamethasone Drugs 0.000 claims description 5
- AVPCPPOOQICIRJ-UHFFFAOYSA-L sodium glycerol 2-phosphate Chemical compound [Na+].[Na+].OCC(CO)OP([O-])([O-])=O AVPCPPOOQICIRJ-UHFFFAOYSA-L 0.000 claims description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 210000000648 angioblast Anatomy 0.000 claims description 4
- 210000003725 endotheliocyte Anatomy 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 3
- 229960001701 chloroform Drugs 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 37
- 239000010410 layer Substances 0.000 abstract description 29
- 230000007547 defect Effects 0.000 abstract description 6
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 238000004113 cell culture Methods 0.000 abstract description 4
- 238000006731 degradation reaction Methods 0.000 abstract description 4
- 230000001900 immune effect Effects 0.000 abstract description 3
- 239000011229 interlayer Substances 0.000 abstract 1
- 239000004065 semiconductor Substances 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 210000003606 umbilical vein Anatomy 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 244000309466 calf Species 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 4
- 239000012620 biological material Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 101001089018 Ulex europaeus Anti-H(O) lectin 1 Proteins 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000024835 cytogamy Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000001644 umbilical artery Anatomy 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 102100024210 CD166 antigen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012227 artificial bone substitute Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000000080 chela (arthropods) Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000002365 multiple layer Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
Abstract
A kind of tissue engineered bone disclosed by the invention is the multi-layer cellular sheet lamination compound with three-dimensional wick vasoganglion, described multi-layer cellular sheet lamination compound is made up of the stacked mesenchymal stem cells MSCs sheet of n sheet and the vascular endothelial cell that is filled in each mesenchymal stem cells MSCs sheet interlayer, n=3 ~ 8.Its preparation method is: first prepare photosensitive semiconductor structural sheet on the surface in cell culture vessel, obtain photosensitive Tissue Culture Dish; Cultivate mesenchymal stem cells MSCs with photosensitive Tissue Culture Dish again, and obtain mesenchymal stem cells MSCs sheet; Finally building the multi-layer cellular sheet lamination compound be made up of multilayer mesenchymal stem cells MSCs sheet and vascular endothelial cell, obtaining tissue engineered bone through cultivating.Tissue engineered bone of the present invention is made up of homologous cell merely, reduces the pollution that immunological rejection and scaffold degradation cause, to the reparation of Cranial defect and early stage vascularization significant, and method of the present invention is simple, is convenient to promote.
Description
Technical field
The present invention relates to a kind of tissue engineered bone and preparation method thereof, be specifically related to a kind of tissue engineered bone be made up of multi-layer cellular sheet and preparation method thereof, belong to field of tissue engineering technology.
Background technology
The osseous tissue defect caused due to congenital malformation, wound, tumour etc. and disappearance are clinical common diseases, are therefore the important topic of regenerative medicine to the functional reconstruction reparation of osseous tissue defect always.Traditional methods for the treatment of often adopts autologous or allogenic bone transplantation, but often because supply source is limited or immunological rejection etc. and limit its clinical application.Tissue engineering technique, as the one be most widely used in current artificial bone substitute materials, is replaced gradually by its biodegradability.Disclosed in CN103285427A " a kind of artificial bone and preparation method thereof ", namely adopt suitable proportion hydroxyapatite, collagen and nano-cellulose synthesis artificial bone, there is good intensity and degradation property.CN103157138A disclosed " a kind of construction process of tissue engineering bone renovation material ", then adopt injectable type chitosan-bata-tricalcium phosphate compound bone marrow stroma stem cell as tissue engineered bone, can random-shaping and degradable absorption, induced osteogenesis effect is obvious.But, the cell adhesion of conventional organization engineering mainly through repair district's periphery cell creep or by corresponding cell suspension titration in material surface or defective region, cell adhesion utilization ratio is low, repairing efficiency is long, and its size, shape and location are also difficult to control; Meanwhile, titration cell suspension is often formed and is dispersed in island and repairs district, inapplicable for large stretch of tissue defect; In addition, applying biological bone tissue constructed by traditional organizational project, to implant after host angiogenesis in it slow, be unfavorable for the growth of osseous tissue, reconstruction and timbering material degraded, therefore build the novel tissue Engineering Bone with initial stage vascularization the reparation of osseous tissue and reconstruction are had great importance.
Cell thin culture technique (TangZ; AkiyamaY; YamatoM, OkanoT.Comb-typegraftedpoly (N-isopropylacrylamide) gelmodifiedsurfacesforrapiddetachmentofcellsheet.Biomate rials (2010); 31 (29): 7435-43.NagaseK; KobayashiJ; KikuchiA; AkiyamaY; KanazawaH, OkanoT.Thermally-modulatedon/off-adsorptionmaterialsforp harmaceuticalproteinpurification.Biomaterials. (2011); 32 (2): 619-27.) as a kind of novel tissue engineering method, there is the advantage of its uniqueness.It is by corresponding intermediary material or control hydrophobe-hydrophile conversion bottom attached cell institute grown cultures ware thus control cell adhere to growth in flakes and peel off, after this " cell sheet " multiple-layer stacked or compound criteria, without the need to lapping, itself namely can be used as one " biological support " and implant defect.Compare pancreatin effect obtain cell, its do not destroy intercellular albumen connect and cell with the connection between bottom substrates, cytoactive is better; Meanwhile, the problem of high pollution is caused when cell thin culture technique also can be avoided being reduced in tissue repair because using biological degradation timbering material.CN103097518A and CN103180437A disclosed " manufacture method of cell sheet lamination compound, the cell sheet lamination compound with vasoganglion obtained by the method and Application way thereof ", namely cell sheet is obtained by temperature sensitive Tissue Culture Dish, the superposition of multi-layer cellular sheet is formed cladding cell sheet lamination compound, and its entirety is incubated on the vescular bed that forms containing stream gel or arteriovenous loop, obtain the cardiac muscular tissue containing vasoganglion.But; the condition relative complex of temperature control; higher for equipment requirements, between temperature or change and also affect the activity of cell, accelerating part cell senescence; the people skeletonization class cell more responsive for temperature inapplicable (FukumoriK; AkiyamaY, YamatoM, KobayashiJ; SakaiK, OkanoT.Temperatureresponsiveglasscoverslipswithanultrath inpoly (N-isopropylacrylamide) layer.ActaBiomater2009; 5:470-476).
Summary of the invention
The object of the present invention is to provide a kind of tissue engineered bone be made up of multi-layer cellular sheet with plexus structure and preparation method thereof.
Tissue engineered bone of the present invention is the multi-layer cellular sheet lamination compound with three-dimensional wick vasoganglion, described multi-layer cellular sheet lamination compound is made up of the stacked mesenchymal stem cells MSCs sheet of n sheet and the vascular endothelial cell be filled between each mesenchymal stem cells MSCs sheet, n=3 ~ 8.
Prepare the method for above-mentioned tissue engineered bone, comprise the steps:
1) photosensitive Tissue Culture Dish is prepared
Photoresponse nanoparticulate dispersed is made into the dispersion liquid that mass concentration is 10 ~ 20% in deionized water, the proportions being 0.02 ~ 0.06:6 ~ 9:1 ~ 3 in molar ratio by dispersion liquid and alcohol and organic solvent again becomes precursor solution, precursor solution is dropped to polystyrene culture dish be paved with to it, dry and sterilize, obtaining photosensitive Tissue Culture Dish; Described photoresponse nano particle is nano-titanium oxide, nano zine oxide or nano-sized iron oxide, and alcohol is methyl alcohol or ethanol, and organic solvent is tetrahydrofuran (THF), trichloromethane or methylene dichloride;
2) mesenchymal stem cells MSCs sheet is cultivated
Get mesenchymal stem cells MSCs, with 5 × 10
4~ 2 × 10
5individual/cm
2density implantation step 1) photosensitive Tissue Culture Dish in, add mesenchymal stem cells MSCs special culture media and cultivate after 4 ~ 10 days, adopt wavelength 320 ~ 450nm, intensity 1 ~ 4mW/cm
2light inject bottom culture dish, expose to mesenchymal stem cells MSCs fall in flakes in photosensitive Tissue Culture Dish, obtain mesenchymal stem cells MSCs sheet;
3) tissue engineered bone is built
By step 2) the mesenchymal stem cells MSCs sheet that obtains is transferred in Tissue Culture Dish, after it is adherent, adds mesenchymal stem cells MSCs special culture media, at 37 DEG C, 5%CO
2and after cultivating 2 ~ 48h under saturated humidity condition, with 5 × 10
4~ 2 × 10
5individual/cm
2density implantable intravascular endotheliocyte thereon, then at 37 DEG C, 5%CO
2and cultivate 2 ~ 48h under saturated humidity condition, after absorbing mesenchymal stem cells MSCs special culture media, said structure shifts a slice mesenchymal stem cells MSCs sheet again, adds mesenchymal stem cells MSCs special culture media, at 37 DEG C, 5%CO
2and cultivate 2 ~ 48h under saturated humidity condition;
Again with 5 × 10 on said structure
4~ 2 × 10
5individual/cm
2density implantable intravascular endotheliocyte thereon, at 37 DEG C, 5%CO
2and cultivate 2 ~ 48h under saturated humidity condition, after absorbing mesenchymal stem cells MSCs special culture media, again shift mesenchymal stem cells MSCs sheet, and add mesenchymal stem cells MSCs special culture media, at 37 DEG C, 5%CO
2and cultivate 2 ~ 48h under saturated humidity condition, repeat above-mentioned process until this structure has n layer mesenchymal stem cells MSCs sheet, n=3 ~ 8, obtain multi-layer cellular sheet lamination compound, scleroblast inducible factor and angioblast inducible factor is added, at 37 DEG C, 5%CO in the mesenchymal stem cells MSCs special culture media in Tissue Culture Dish
2and cultivate 4 ~ 10 days again under saturated humidity condition, obtain tissue engineered bone.
Described scleroblast inducible factor is one or more in xitix, sodium β-glycerophosphate and dexamethasone, and its addition can be xitix 50 ~ 100ug/ml, sodium β-glycerophosphate 5 ~ 10mM and dexamethasone 1 × 10 respectively
-8m ~ 1uM; Described angioblast inducible factor is one or both in vascular endothelial growth factor and Prostatropin, and its addition can be Prostatropin 5 ~ 10ng/ml and vascular endothelial growth factor 10 ~ 20ng/ml respectively.
Mesenchymal stem cells MSCs involved in the present invention can be differentiation-inducing or be extracted from marrow, fatty tissue, peripheral blood, fetal blood or liver by embryo stem cell for directional, and vascular endothelial cell can be differentiation-inducing or be extracted from marrow, peripheral blood or Cord blood by embryo stem cell for directional.Because mesenchymal stem cells MSCs source is different; basic medium needed for it is not identical yet; therefore the mesenchymal stem cells MSCs special culture media described in the present invention refers to the substratum corresponding with the source of mesenchymal stem cells MSCs, specifically can with reference to such as Publication about Document: Smalldiametervasculargraftengineeredusinghumanembryonics temcell-derivedmesenchymalcells(TissueEngPartA.2014Feb; 20 (3-4): 740-50), Differentiationofhumanembryonicstemcellsintobipotentmese nchymalstemcells(OlivierE, etal., StemCells200624:1914-1922) and the optimization culture of human marrow-interstitial stem cell (Pang Yong firm Chen Wen string Cui distance of travel of roc, " Chinese Reconstructive surgery magazine " 2004(3) 220-224).
Compared with prior art, the present invention has following useful technique effect:
1. the present invention obtains mesenchymal stem cells MSCs sheet by photosensitive cell culture dish, namely photoresponse film surface charging property and group is caused to change by UV-light or radiation of visible light, thus make growth cell thereon obtain cell sheet from the overall desorption of corresponding vessel surface, compared to existing cell thin technology, method of the present invention is more convenient, efficiency is higher, meanwhile, and the phenomenon such as aging, downright bad avoiding that the people skeletonization class cell more responsive to temperature produce because of temperature change.
2. the tissue engineered bone that there is plexus structure and be made up of multilayer mesenchymal stem cells MSCs sheet lamination compound of the present invention, compared to existing artificial bone, without the need to biomaterial as rack bearing, be made up of homologous cell merely, reduce the pollution that immunological rejection and scaffold degradation cause, and define the novel tissue Engineering Bone with three-dimensional plexus structure in external, to the reparation of Cranial defect and early stage vascularization significant.
Accompanying drawing explanation
Fig. 1 is the macrograph of multilayer mesenchymal stem cells MSCs sheet lamination compound
Fig. 2 is inverted microscope figure below of multilayer mesenchymal stem cells MSCs sheet lamination compound
Wherein a: multi-disc cell sheet neighboring area b: multi-disc cell sheet region intermediate
Fig. 3 is the specificity fluorescent signature of tissue engineered bone Endothelial Cell
Wherein a: Surface of Vascular Endothelial Cells Specific marker CD31
B: vascular endothelial cell specific markers UEA-I
C: nuclear marker thing.
Embodiment
Below in conjunction with specific embodiment, the present invention is described further, but implementation of the present invention is not limited thereto.
Embodiment one
1) photosensitive cell culture dish is prepared
Titanium dioxide nanoparticle is dispersed in water and forms the dispersion liquid that mass concentration is 20%, dispersion liquid and methyl alcohol and tetrahydrofuran (THF) are made into precursor solution in the ratio of 0.06:9:3; Again above-mentioned precursor solution is pressed 48 μ L/cm
2evenly be added drop-wise in polystyrene culture dish, put into 65 DEG C of baking ovens dry, can obtain that to comprise grain-size be 20 ~ 30nm after drying, thickness is the Tissue Culture Dish of the photoresponse nanophase titania films of 60nm ~ 100nm;
2) mesenchymal stem cells MSCs sheet is cultivated
Get 3 ~ 5 generation human marrow mesenchyme stem cells, with 2 × 10
5individual/cm
2density implanted diameter be 5cm containing in the culture dish of nano-titanium oxide, cultivate after 10 days, employing wavelength 450nm, intensity 4mW/cm
2uv irradiating 5min, obtain the human marrow mesenchymal stem cell sheet of fall in flakes;
3) tissue engineered bone is built
Adopting novel cell sheet transfer interlock instrument by step 2) obtained individual layer human marrow mesenchymal stem cell sheet is transferred in regular growth culture dish, after it is adherent, add stem cell special culture media (containing 10% foetal calf serum, L-glutaminate 2mmol/L, penicillin 100U/ml, Streptomycin sulphate 100mg/ml), be placed in 37 DEG C, 5%CO
2after cultivating 48h under saturated humidity condition, with 2 × 10
5individual/cm
2density implant human umbilical vein endothelial cell thereon, under above-mentioned culture condition, place 2h, absorb after substratum, with novel cell sheet transfer interlock instrument, second layer human marrow mesenchymal stem cell sheet is transferred on it, quiescent culture 2h under the same terms.Subsequently, then with 2 × 10
5individual/cm
2density implant one deck human umbilical vein endothelial cell thereon, and cultivate 2h under the same terms, finally third layer human marrow mesenchymal stem cell sheet is transferred on it, the multi-layer cellular sheet lamination compound of three layers of human marrow mesenchymal stem cell sheet and double layer sandwich human umbilical vein endothelial cell must be comprised, figure mono-is the macrograph of multi-layer cellular sheet lamination compound, second figure is the inverted microscope figure (a of corresponding multi-layer cellular sheet lamination compound, b represents periphery and the region intermediate of multi-layer cellular sheet respectively), adhere to good between display multi-layer cellular, have no obvious floating dead cell.Extra interpolation Prostatropin 10ng/ml and vascular endothelial growth factor 20ng/ml in above-mentioned stem cell special culture media, and add scleroblast inducible factor xitix 100ug/ml, sodium β-glycerophosphate 10mM and dexamethasone 1uM, namely vitro culture obtains the tissue engineered bone with plexus structure after 4 days, figure tri-is tissue engineered bone Endothelial Cell specificity fluorescent signature (a, b represents that Surface of Vascular Endothelial Cells Specific marker CD31 and UEA-I dyes respectively), between display lamination compound, vascular endothelial cell forms plexus structure gradually.
The concrete source of the human marrow mesenchymal stem cell used in this example is illustrated:
Obtain young bone grafting patient to agree to, ilium gets bone, 10ml bone marrow fluid is drawn with syringe, the heparin sodium 2500U/ml that syringe includes dilution is about 0.5ml, by adherent for cell suspension be slowly injected into preset equal-volume density be the human lymphocyte parting liquid of 1.077kg/L in vitro, make to form interface clearly between the two.With the centrifugal 20min of 2500r/min, oyster white cloud mononuclear cell layer in the middle of drawing, PBS rinsing, the centrifugal 10min of 1500r/min, abandon supernatant, add human marrow mesenchymal stem cell special culture solution (Jiangsu Celeron the is biological) 10ml containing 10% calf serum, make single cell suspension, be inoculated in floorage for 25cm with suitable density
2in culturing bottle, insert 37 DEG C, 5%CO
2cultivate under saturated humidity condition, after 4 days, half amount changes liquid first, and all discarded by not adherent cell, within later every 2 ~ 3 days, full dose changes liquid once.Become after individual layer until cell confluency, with 0.25% trypsin containing 0.02%EDTA) digestion, namely obtain Primary bone marrow mesenchyma stem cell suspension.Treat that cytogamy reaches more than 80%, by 1: 3 or 1: 4 Secondary Culture, get the attached cell that the growth of the 3rd generation reaches 80% fusion, with tryptic digestion, after counting, get 2 × 10
6individual cell, packing 6 is managed, and often pipe adds 10 μ l fluorescent-labeled antibody CD45-FITC, CD34-PE, CD73-PE, CD105-FITC, CD166-PE, separately sets 1 pipe as blank, room temperature lucifuge 30min, repeatedly wash 2-3 time with PBS, add 200 μ lPBS and mix cell, and fix with 1% paraformaldehyde, 4 DEG C of preservations, in 24h, flow cytometer detects, and Normal Human Bone Marrow mescenchymal stem cell high expression level CD73, CD105 and CD166, CD34 and CD45 is then negative.
The concrete source of the human umbilical vein endothelial cell used in this example is illustrated:
Aseptic acquisition neonatal umbilical cord, use normal saline flushing bloodstain immediately, cut off pincers trace and Hemorrhagic location, find out umbilical vein (2 tube chambers less be Umbilical artery, what 1 tube chamber was thicker is umbilical vein), umbilical vein is inserted from one section with the syringe of the flat syringe needle of band, fix with vascular clamp, bloodstain in umbilical vein is washed down again with PBS liquid, for preventing the residual blood of Umbilical artery to be mixed into, artery can be separated a little sterilization toe-in and prick, with the vascular clamp clamp the other end, the collagenase liquid injecting 0.1% from the syringe needle rinsed makes it fill, and puts into 37 DEG C of water-baths and hatches 15min.Take out umbilical cord and unclamp vascular clamp release enzyme cell mixture in centrifuge tube, be collected in the lump in centrifuge tube after rinsing umbilical vein with PBS liquid again, 1000r/min, centrifugal 5min, abandon supernatant, add DMEM nutrient solution (containing 10% foetal calf serum, L-glutaminate 2mmol/L, penicillin 100U/ml, Streptomycin sulphate 100mg/ml, Prostatropin 10ng/ml, vascular endothelial growth factor 20ng/ml), be placed in 37 DEG C, 5%CO
2cultivate under saturated humidity condition, after 24h, change liquid first, within later every 2 ~ 3 days, change liquid once.Treat that cytogamy reaches more than 80%, by 1: 3 or 1: 4 Secondary Culture, get the attached cell that the growth of the 3rd generation reaches 80% fusion, with 0.25% trypsin containing 0.02%EDTA) digestion, after PBS cleaning for several times, add 20 μ l fluorescent-labeled antibody CD31-PE, separately establish blank, row flow cytometry after room temperature lucifuge 30min, normal people's umbilical vein vascular endothelial cells high expression level CD31.
Embodiment two
1) photosensitive cell culture dish is prepared
Zinc oxide nanoparticle is dispersed in water and forms the dispersion liquid that mass concentration is 10%, dispersion liquid and ethanol and trichloromethane are made into precursor solution in the ratio of 0.02:6:1, then by above-mentioned precursor solution by 25 μ L/cm
2evenly be added drop-wise in polystyrene culture dish, put into 65 DEG C of baking ovens dry, can obtain that to comprise grain-size be 10 ~ 20nm after drying, thickness is the Tissue Culture Dish of the photoresponse Nano zinc oxide film of 40nm ~ 80nm.
2) mesenchymal stem cells MSCs is cultivated
Get the homology human marrow mesenchymal stem cell after cultivating number generation, with 5 × 10
4individual/cm
2density implanted diameter be 5cm containing in the culture dish of nano zine oxide, cultivate after 4 days, employing wavelength 320nm, intensity 1mW/cm
2uv irradiating 30min, obtain the human marrow mesenchymal stem cell sheet of fall in flakes.
3) tissue engineered bone is built
Novel cell sheet transfer interlock instrument is adopted to be transferred in regular growth culture dish by individual layer homology human marrow mesenchymal stem cell sheet, after it is adherent, add stem cell special culture media (containing 10% foetal calf serum, L-glutaminate 2mmol/L, penicillin 100U/ml, Streptomycin sulphate 100mg/ml), be placed in 37 DEG C, 5%CO
2after cultivating 2h under saturated humidity condition, with 5 × 10
4individual/cm
2density implant homology human vascular endothelial thereon, 48h is placed under above-mentioned culture condition, after absorbing substratum, with novel cell sheet transfer interlock instrument, second layer homology human marrow mesenchymal stem cell sheet is transferred on it, quiescent culture 48h under the same terms.Subsequently, repeat to implant homology human vascular endothelial successively and cultivate and shift human marrow mesenchymal stem cell sheet and cultivate, until this structure has 8 layers of mesenchymal stem cells MSCs sheet, obtain multi-layer cellular sheet lamination compound, extra interpolation 5ng/ml Prostatropin and 10ng/ml vascular endothelial growth factor in above-mentioned substratum, and add scleroblast inducible factor xitix 50ug/ml, sodium β-glycerophosphate 5mM and dexamethasone 1 × 10
-8m, namely vitro culture obtained tissue engineered bone after 10 days.
The concrete source of the mesenchymal stem cells MSCs used in this example is illustrated:
Human embryo stem cell field planting is incubated on inactivation mouse fibroblast feeder layer, add DMEM/F12 nutrient solution (containing 20% serum substitute, 1mML-glutamine, 1% non-essential amino acid, 100mM beta-mercaptoethanol, 4ng/ml Prostatropin), treat that its periphery occurs in clastic from noble cells group, get this scrappy cell sheet and cultivate several weeks in containing the human marrow mesenchymal stem cell special culture solution (Jiangsu Celeron is biological) of 10% calf serum, with comprising pancreatin, the mixed solution of IV Collagenase Type and neutral protease dissociates, cultivate again, and go out CD45 by selected by flow cytometry apoptosis, CD34 is negative, and SH2, SH3, the homology human marrow mesenchymal stem cell that SH4 is positive.(human embryo stem cell is given in NUS)
The concrete source of the vascular endothelial cell used in this example is illustrated:
Human embryo stem cell field planting is incubated on inactivation mouse fibroblast feeder layer, add DMEM/F12 nutrient solution (containing 20% serum substitute, 1mML-glutamine, 1% non-essential amino acid, 100mM beta-mercaptoethanol, 4ng/ml Prostatropin), and urge Differentiation after 2 days by 20ng/mlBMP-4, form embryoid body.Subsequently, be colonizated in matrigel surface, add DMEM nutrient solution (containing 10% foetal calf serum, L-glutaminate 2mmol/L, penicillin 100U/ml, Streptomycin sulphate 100mg/ml, Prostatropin 5ng/ml, vascular endothelial growth factor 10ng/ml) separately urge differentiation more than 10 in the future, take CD31 as the vascular endothelial cell that mark filters out people's embryonic stem cells source.(human embryo stem cell is given in NUS)
Claims (2)
1. the preparation method of a tissue engineered bone, described tissue engineered bone is the multi-layer cellular sheet lamination compound with three-dimensional wick vasoganglion, described multi-layer cellular sheet lamination compound is made up of the stacked mesenchymal stem cells MSCs sheet of n sheet and the vascular endothelial cell be filled between each mesenchymal stem cells MSCs sheet, n=3 ~ 8, its preparation comprises the steps:
1) photosensitive Tissue Culture Dish is prepared
Photoresponse nanoparticulate dispersed is made into the dispersion liquid that mass concentration is 10 ~ 20% in deionized water, the proportions being 0.02 ~ 0.06:6 ~ 9:1 ~ 3 in molar ratio by dispersion liquid and alcohol and organic solvent again becomes precursor solution, precursor solution is dropped to polystyrene culture dish be paved with to it, dry and sterilize, obtaining photosensitive Tissue Culture Dish; Described photoresponse nano particle is nano-titanium oxide, nano zine oxide or nano-sized iron oxide, and alcohol is methyl alcohol or ethanol, and organic solvent is tetrahydrofuran (THF), trichloromethane or methylene dichloride;
2) mesenchymal stem cells MSCs sheet is cultivated
Get mesenchymal stem cells MSCs, with 5 × 10
4~ 2 × 10
5individual/cm
2density implantation step 1) photosensitive Tissue Culture Dish in, add mesenchymal stem cells MSCs special culture media and cultivate after 4 ~ 10 days, adopt wavelength 320 ~ 450nm, intensity 1 ~ 4mW/cm
2light inject bottom culture dish, expose to mesenchymal stem cells MSCs fall in flakes in photosensitive Tissue Culture Dish, obtain mesenchymal stem cells MSCs sheet;
3) tissue engineered bone is built
By step 2) the mesenchymal stem cells MSCs sheet that obtains is transferred in Tissue Culture Dish, after it is adherent, adds mesenchymal stem cells MSCs special culture media, at 37 DEG C, 5%CO
2and after cultivating 2 ~ 48h under saturated humidity condition, with 5 × 10
4~ 2 × 10
5individual/cm
2density implantable intravascular endotheliocyte thereon, then at 37 DEG C, 5%CO
2and cultivate 2 ~ 48h under saturated humidity condition, after absorbing mesenchymal stem cells MSCs special culture media, said structure shifts a slice mesenchymal stem cells MSCs sheet again, adds mesenchymal stem cells MSCs special culture media, at 37 DEG C, 5%CO
2and cultivate 2 ~ 48h under saturated humidity condition;
Again with 5 × 10 on said structure
4~ 2 × 10
5individual/cm
2density implantable intravascular endotheliocyte thereon, at 37 DEG C, 5%CO
2and cultivate 2 ~ 48h under saturated humidity condition, after absorbing mesenchymal stem cells MSCs special culture media, again shift mesenchymal stem cells MSCs sheet, and add mesenchymal stem cells MSCs special culture media, at 37 DEG C, 5%CO
2and cultivate 2 ~ 48h under saturated humidity condition, repeat above-mentioned process until this structure has n layer mesenchymal stem cells MSCs sheet, n=3 ~ 8, obtain multi-layer cellular sheet lamination compound, scleroblast inducible factor and angioblast inducible factor is added, at 37 DEG C, 5%CO in the mesenchymal stem cells MSCs special culture media in Tissue Culture Dish
2and cultivate 4 ~ 10 days again under saturated humidity condition, obtain tissue engineered bone.
2. the preparation method of tissue engineered bone according to claim 1, it is characterized in that described scleroblast inducible factor is one or more in xitix, sodium β-glycerophosphate and dexamethasone, described angioblast inducible factor is one or both in vascular endothelial growth factor and Prostatropin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410480554.6A CN104225681B (en) | 2014-09-19 | 2014-09-19 | A kind of tissue engineered bone and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410480554.6A CN104225681B (en) | 2014-09-19 | 2014-09-19 | A kind of tissue engineered bone and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104225681A CN104225681A (en) | 2014-12-24 |
| CN104225681B true CN104225681B (en) | 2016-03-02 |
Family
ID=52215150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410480554.6A Active CN104225681B (en) | 2014-09-19 | 2014-09-19 | A kind of tissue engineered bone and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104225681B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581759A (en) * | 2016-11-08 | 2017-04-26 | 华南生物医药研究院 | Tissue-engineering bone |
| CN106581066B (en) * | 2016-11-08 | 2020-07-03 | 华南生物医药研究院 | Use of tissue engineering bone |
| CN106563160A (en) * | 2016-11-08 | 2017-04-19 | 华南生物医药研究院 | Method for preparing tissue-engineered bone |
| CN106924817B (en) * | 2017-03-02 | 2019-12-17 | 浙江大学 | Ultrathin carrier cell sheet and preparation method thereof |
| CN107050517B (en) * | 2017-05-04 | 2020-06-02 | 宁夏医科大学 | Vascularized tissue engineering bone without exogenous support and its prepn |
| CN112004922A (en) * | 2018-04-25 | 2020-11-27 | 北海道公立大学法人札幌医科大学 | Cell sheet for biological transplantation and method for producing same |
| US11866483B2 (en) | 2018-06-08 | 2024-01-09 | Kanoncure, Inc. | Fibrosis-inhibiting composition, cells producing same, and cell sheet comprising said cells |
| CN108467837B (en) * | 2018-06-15 | 2023-08-18 | 上海天引生物科技有限公司 | Visual multichannel fluid shear force cell culture device and method thereof |
| CN111821518B (en) * | 2019-04-15 | 2023-01-10 | 弗元(上海)生物科技有限公司 | Preparation method of tissue engineering bone with regeneration capacity |
| CN110201232B (en) * | 2019-06-06 | 2020-10-23 | 中国人民解放军第四军医大学 | Preparation method of self-assembled prevascularized stem cell membrane |
| CN111249528B (en) * | 2020-01-20 | 2021-07-16 | 浙江大学 | Tissue engineering bone based on multilayer cell grid and preparation method thereof |
| CN111849884B (en) * | 2020-07-30 | 2021-02-19 | 山东天川精准医疗科技有限公司 | Induction method for directional differentiation of human placental amniotic membrane stem cells into hepatocytes |
| CN113368308B (en) * | 2021-06-07 | 2022-07-26 | 北京市创伤骨科研究所 | Bionic sandwich-structured artificial periosteum and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101896600A (en) * | 2007-12-10 | 2010-11-24 | 皇家飞利浦电子股份有限公司 | The cell sheets of patterning and its production method |
| CN103097518A (en) * | 2010-09-14 | 2013-05-08 | 学校法人东京女子医科大学 | Method for manufacturing multilayered cell sheet, multilayered cell sheet having vascular network obtained thereby, method of use thereof |
| CN103180437A (en) * | 2010-09-14 | 2013-06-26 | 学校法人东京女子医科大学 | Method for producing layered cell sheets, layered cell sheets having vascular network obtained thereby, and method for utilizing same |
| CN103767804A (en) * | 2014-01-20 | 2014-05-07 | 清华大学 | Vascularizing tissue structure with microfluid passage and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2218772A1 (en) * | 2009-02-09 | 2010-08-18 | Koninklijke Philips Electronics N.V. | Cardiomyocytes-containing device and method for manufacturing the same |
| US9701939B2 (en) * | 2011-04-08 | 2017-07-11 | The University Of Akron | Thermoresponsive cell culture supports |
-
2014
- 2014-09-19 CN CN201410480554.6A patent/CN104225681B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101896600A (en) * | 2007-12-10 | 2010-11-24 | 皇家飞利浦电子股份有限公司 | The cell sheets of patterning and its production method |
| CN103097518A (en) * | 2010-09-14 | 2013-05-08 | 学校法人东京女子医科大学 | Method for manufacturing multilayered cell sheet, multilayered cell sheet having vascular network obtained thereby, method of use thereof |
| CN103180437A (en) * | 2010-09-14 | 2013-06-26 | 学校法人东京女子医科大学 | Method for producing layered cell sheets, layered cell sheets having vascular network obtained thereby, and method for utilizing same |
| CN103767804A (en) * | 2014-01-20 | 2014-05-07 | 清华大学 | Vascularizing tissue structure with microfluid passage and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| ed surfaces for rapid detachment of cell sheet.《Biomaterials》.2010,第31卷7435-7443. * |
| Thermally-modulated on/off-adsorption materials for pharmaceutical protein purification;Kenichi Nagase等;《Biomaterials》;20101002;第32卷;619-627 * |
| Zhonglan Tang等.Comb-type grafted poly(N-isopropylacrylamide)gel modifi * |
| 细胞片工程在组织工程中的应用;邓林红等;《中国组织工程研究与临床康复》;20101008;第14卷(第41期);7715-7718 * |
| 细胞片技术的应用现状;刘珍伶等;《中华临床医师杂志》;20121130;第6卷(第22期);7338-7340 * |
| 细胞膜片技术及其在骨组织领域的应用进展;陈亚莉等;《中国修复重建外科杂志》;20120930;第26卷(第9期);1122-1125 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104225681A (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104225681B (en) | A kind of tissue engineered bone and preparation method thereof | |
| Matsuda et al. | Tissue engineering based on cell sheet technology | |
| JP6130588B2 (en) | Mesenchymal stem cell-hydrogel-biodegradable or mesenchymal stem cell-hydrogel-non-degradable support composition for skin regeneration or wound healing | |
| Mazlyzam et al. | Reconstruction of living bilayer human skin equivalent utilizing human fibrin as a scaffold | |
| US20170304366A1 (en) | Composition containing mesenchymal stem cell-hydrogel and method for producing the composition | |
| Zhe et al. | Bladder acellular matrix grafts seeded with adipose-derived stem cells and incubated intraperitoneally promote the regeneration of bladder smooth muscle and nerve in a rat model of bladder augmentation | |
| Fu et al. | Degradable chitosan-collagen composites seeded with cells as tissue engineered heart valves | |
| CN111249528B (en) | Tissue engineering bone based on multilayer cell grid and preparation method thereof | |
| CN104312970A (en) | Preparation method of clinical treatment level epidermal stem cell for cell therapy by applying human extracellular matrix screening and mass culture | |
| Lee et al. | A prototype tissue engineered blood vessel using amniotic membrane as scaffold | |
| Zhang et al. | Hypoxia created human mesenchymal stem cell sheet for prevascularized 3D tissue construction | |
| WO2011058813A1 (en) | Cell sheet for myocardial regeneration, manufacturing method, and method of usage therefor | |
| Xu et al. | Controlled adipose-derived stromal cells differentiation into adipose and endothelial cells in a 3D structure established by cell-assembly technique | |
| EP2617438B1 (en) | Middle ear mucous membrane-like cell sheet, production method therefor and utilization thereof | |
| Prgeeth Pandula et al. | Human umbilical vein endothelial cells synergize osteo/odontogenic differentiation of periodontal ligament stem cells in 3 D cell sheets | |
| Nishiwaki et al. | In situ transplantation of adipose tissue‐derived stem cells organized on porous polymer nanosheets for murine skin defects | |
| Li et al. | Stem cells cardiac patch from decellularized umbilical artery improved heart function after myocardium infarction | |
| CN107137763A (en) | A kind of study of vascularized tissue engineering bone and preparation method thereof | |
| CN109609461A (en) | A kind of primary tumor cell isolated culture method | |
| CN106552295A (en) | A kind of bilayer skin containing blood capillary tube chamber and preparation method thereof | |
| CN104450606A (en) | Eccrine sweat gland cell induction medium and application thereof | |
| CN103215218B (en) | Method for separating and culturing endothelial clone formative cell | |
| CN106282094B (en) | The method that the precursor in application on human skin source is induced to differentiate into corneal endothelium like cell | |
| EP3315601B1 (en) | Method for culturing animal cell composition, method for producing animal cell composition using same, and animal cell composition | |
| CN102552997A (en) | Pericardium with stem cell, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |